

14 Mar 2017 |

Big Pharma Outlook 2025, An Infographic

by Jo Shorthouse

Big Pharma is poised for growth because of strong launch portfolios, the availability of high-potential pipeline assets, and a focus on high-performing markets. This outlook has been created using in-house sales forecasts from the 16 companies that form Datamonitor Healthcare's Big Pharma peer set.

Infographic: Big Pharma Outlook to 2025

BIG PHARMA OUTLOOK TO 2025



Big Pharma is poised for growth because of strong launch portfolios, the availability of high-potential pipeline assets, and a focus on high-performing markets. This outlook has been created using in-house sales forecasts from the 16 companies that form **Datamonitor Healthcare's** Big Pharma peer set.

Big Pharma
prescription drug
sales grow to
\$464bn
by 2025.



Pfizer sustains
top ranking in
prescription drug sales.



Humira will continue
to be the highest
selling product with
global sales forecast at
\$11bn



Big Pharma's launch
portfolio is set to add
\$134bn
in revenues.

2015

Infectious
diseases

2020


Oncology will supplant Infectious diseases as
the most valuable therapy area in Big Pharma.



REVENUES

2020: Big Pharma will add \$17.8bn in sales, similar in magnitude to growth between 2010 and 2015, which saw a \$15.3bn gain.

2025: Big Pharma will add \$39bn in revenues out to 2025, generating \$464bn in prescription pharmaceuticals sales.



2016-2018: Stagnant revenues are expected owing to the onset of biosimilar competition.

2020-2025: Growth is expected to decelerate owing to maturing portfolios.

REGIONAL GROWTH

Big pharma will have a 0.8% CAGR out to 2025 in the **5EU*** region. Novartis is forecast to maintain its leadership in the 5EU out to 2025. AbbVie will exhibit the most growth. Humira will sustain its status as the region's leading product.

Several companies will see declining sales in **Japan**, where the overall Big Pharma CAGR will be 0.4% out to 2025.